Feb 19, 2020
New Data Show Oral Ferric Maltol (FERACCRU®) May Be a Cost-effective Alternative to Intravenous (IV) Carboxymaltose With at Least as Great Benefits in the Quality of Life of Patients With Iron Deficiency Anaemia and Inflammatory Bowel Disease
Feb 10, 2020
Pharmacosmos Therapeutics Inc. established as a new specialty pharmaceutical company to bring recently approved treatment option to iron deficiency anemia patients
May 30, 2019
$7.69 Bn IV and Oral Iron Drugs Markets - Global Outlook and Forecast 2019-2024
May 22, 2019
The Global IV and Oral Iron Drugs Market is Expected to Reach Around $7.69 Billion During Forecast Period 2018-2024-Market Research by Arizton
Mar 04, 2019
Important New Trial With Oral FERACCRU® Shows Comparable Efficacy to IV Iron (Ferric Carboxymaltose), Offering a Real Alternative to Hospital Administration for Many Patients[4]
Jan 29, 2019
Carrie Ann Inaba Partners with Daiichi Sankyo, Inc. to Encourage Americans to "Get Iron Informed"
Dec 06, 2018
Clinical trial sheds new light on potential risk associated with intravenous iron treatment
Nov 15, 2018
Intravenous (IV) Iron Drugs: The Global Market is Projected to Grow Tremendously During 2018-2022
Nov 01, 2018
Sierra Oncology to Report Clinical Data at ASH 2018 from Translational Biology Study of Momelotinib in Transfusion Dependent Patients
Nov 07, 2017
The Renal Anemia Market is on the Cusp of Change Beginning with the FDA Approval of Keryx Biopharmaceutical's Auryxia for the Treatment of Iron Deficiency Anemia (IDA) in Adults with Chronic Kidney Disease, Not on Dialysis (CKD-ND)
Oct 23, 2017
Global Intravenous (IV) Iron Drugs Market, 2024 - Increasing Trend towards Bundled Reimbursements